Cell Rep: Domestic scholars have made new advances in the study of fever-related platelet-reducing virus-induced inflammatory responses.

!---- recently, the National Key Laboratory of Virology, Peng Yu, and Xiao Yufu's research team published their latest research in the international academic journal Cell Reports online, the paper entitled "SFTSV Infection Induces BAK/BAX-Ritochon dridride DNA to Trigger NLRP3 Inmmaroom activation" (fever-with-hematopathy reduction syndrome-induced bak/BAX-activated mitochondrial DNA releaseFever with platelet reduction syndrome (SFTS) is a new viral and infectious disease first discovered in China and transmitted in East Asia, caused by a new type of tick-borne Bunia virus (SFTSV) infectionThe disease is acute and has a high clinical fatality rate (12-50%)Currently, there is no effective vaccine for SFTSVTherefore, it is urgent to analyze the pathogenic mechanism of SFTSV infection in depth to provide new ideas for the research of clinical treatment planThe team used multi-dimensional group studies of clinical patient sample transcription groups and quantitative proteomics to reveal the potential pathogenic mechanisms of SFTSV infectionA joint analysis of multidimensional histology found that inflammatory responses were highly correlated with disease progression and fatal outcomes, while mitochondrial damage induced by SFTSV infection may be associated with the occurrence of inflammatory responsesFurther mechanism studies have found that SFTSV infection induces oxidation of mitochondrial DNA, activates BAK/BAX to induce the release of mitochondrial DNA in the form of oxidation into the cell, and the mitochondrial DNA in the form of intracellular oxidation binds and activates the NLRP3 inflammatory small body, leading to disease-related inflammatory responseThis study revealed the oxidation and intracytocytic release of Mitochondrial DNA induced by SFTSV infection, further activated the mechanism of NLRP3 inflammatory small body, and provided a theoretical reference for the development of clinical treatment options for SFTSLi Shufen, Assistant Researcher of wuhan Virus Research Institute of the Chinese Academy of Sciences, and Li Hao, researcher of the Institute of Military Medicine of the Academy of Military Sciences, are the co-authors of the article, and Zhang Lei, a researcher at the Wuhan Institute of Virus studies of the Chinese Academy of Sciences, zhang Lei, an associate researcher at the Xiao Weifu team of the Wuhan Institute of Virusstudies of the Chinese Academy of Sciences, and Liu Wei, a researcher at the Institute of Military Medicine of the Academy of Military Sciences, are the co-authors of the articleThe work has been supported by major national science and technology projects, national key research and development programs, the National Natural Science Foundation of China and the Chinese Academy of Sciences strategic pilot science and technology special projects